Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Elena Peira"'
Autor:
Simona Sapino, Giulia Chindamo, Elena Peira, Daniela Chirio, Federica Foglietta, Loredana Serpe, Barbara Vizio, Marina Gallarate
Publikováno v:
Pharmaceutics, Vol 15, Iss 10, p 2472 (2023)
Repeated intravitreal (IVT) injections in the treatment of retinal diseases can lead to severe complications. Developing innovative drug delivery systems for IVT administration is crucial to prevent adverse reactions, but requires extensive investiga
Externí odkaz:
https://doaj.org/article/313a8eaf39a2456eadd7efa6fde93a3a
Publikováno v:
Cosmetics, Vol 10, Iss 2, p 62 (2023)
In this study, an overview of the regulations in force in some extra-EU states belonging to different geoeconomic areas is provided, starting from the current EU legislation on cosmetic products. We focused on their legislative frameworks and the loc
Externí odkaz:
https://doaj.org/article/fd9fc68338da4662916f0f2a650c42dd
Autor:
Simona Sapino, Giulia Chindamo, Daniela Chirio, Silvia Morel, Elena Peira, Cristina Vercelli, Marina Gallarate
Publikováno v:
Nanomaterials, Vol 12, Iss 24, p 4501 (2022)
In recent years, several nanocarrier-based drug delivery systems, such as polymeric nanoparticles, solid lipid nanoparticles, metallic nanoparticles, liposomes, and others, have been explored to target and treat a wide variety of diseases. Their empl
Externí odkaz:
https://doaj.org/article/c97665217b864b748bd604d0e1e17605
Autor:
Elena Peira, Daniela Chirio, Simona Sapino, Konstantin Chegaev, Giulia Chindamo, Iris Chiara Salaroglio, Chiara Riganti, Marina Gallarate
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 19, p 11555 (2022)
Several semisynthetic, low-cardiotoxicity doxorubicin (DOXO) conjugated have been extensively described, considering the risk of cytotoxicity loss against resistant tumor cells, which mainly present drug efflux capacity. Doxorubicin 14-[4-(4-phenyl-5
Externí odkaz:
https://doaj.org/article/715266f0f35444b58fc8b3a9eefa2f23
Autor:
Daniela Chirio, Simona Sapino, Giulia Chindamo, Elena Peira, Cristina Vercelli, Chiara Riganti, Maela Manzoli, Graziana Gambino, Giovanni Re, Marina Gallarate
Publikováno v:
Pharmaceutics, Vol 14, Iss 7, p 1362 (2022)
Osteosarcoma (OSA) is the most frequently diagnosed primary malignant bone tumor in humans and dogs. In both species, standard chemotherapy can be limited by multidrug resistance of neoplastic cells, which prevents intracellular accumulation of cytot
Externí odkaz:
https://doaj.org/article/c28ab6e05017448997e5a80a10400122
Publikováno v:
Pharmaceutics, Vol 14, Iss 3, p 513 (2022)
Current Italian legislation provides that medical Cannabis can be administered orally as an extract if it has been titrated to determine the concentration of active molecules. In this context, there is a need to provide known and adequate quantities
Externí odkaz:
https://doaj.org/article/897bbbdd4c4e4fc7832ead7f34a47537
Autor:
Simona Sapino, Giulia Chindamo, Daniela Chirio, Maela Manzoli, Elena Peira, Chiara Riganti, Marina Gallarate
Publikováno v:
Nanomaterials, Vol 11, Iss 11, p 2983 (2021)
The treatment of bone diseases (including osteoporosis, osteoarthritis, and bone cancer) often results in reduced efficiency and/or adverse reactions due to the fact that it is not specifically targeted to the site of action. The employment of a suit
Externí odkaz:
https://doaj.org/article/d8112b6d9e3342b1ba5f3fabff378314
Autor:
Monica Argenziano, Silvia Arpicco, Paola Brusa, Roberta Cavalli, Daniela Chirio, Franco Dosio, Marina Gallarate, Elena Peira, Barbara Stella, Elena Ugazio
Publikováno v:
Pharmaceutics, Vol 13, Iss 10, p 1538 (2021)
Active targeting is a valuable and promising approach with which to enhance the therapeutic efficacy of nanodelivery systems, and the development of tumor-targeted nanoparticles has therefore attracted much research attention. In this field, the rese
Externí odkaz:
https://doaj.org/article/a3e0a50fcad9453990aea59a2fa91422
Autor:
Daniela Chirio, Elena Peira, Simona Sapino, Giulia Chindamo, Simonetta Oliaro-Bosso, Salvatore Adinolfi, Chiara Dianzani, Francesca Baratta, Marina Gallarate
Publikováno v:
Pharmaceutics, Vol 13, Iss 4, p 560 (2021)
Bevacizumab (BVZ) is a monoclonal antibody that binds to human vascular endothelial growth factor A (VEGF-A) and inhibits the interaction between VEGF-A and VEGF receptors, thus blocking the angiogenesis. Repeated intravitreal injections of BVZ for t
Externí odkaz:
https://doaj.org/article/575ecb3c8dec468288dc4742b169c143
Autor:
Elena Peira, Giulia Chindamo, Daniela Chirio, Simona Sapino, Simonetta Oliaro-Bosso, Erica Rebba, Pavlo Ivanchenko, Marina Gallarate
Publikováno v:
Pharmaceutics, Vol 13, Iss 2, p 258 (2021)
Bevacizumab (BVZ), a recombinant humanized monoclonal antibody, has recently been proposed as a topical application in the treatment of anterior segment neovascularization; however, as there are some disadvantages in the administration of common eye-
Externí odkaz:
https://doaj.org/article/1fdf49590c8e40f1b486e2136bbe5e5a